HER2 Expression in Gastric Adenocarcinoma: A Study in a Tertiary Care Centre in Bahrain | OMICS International | Abstract
ISSN: 2476-2253

Journal of Cancer Diagnosis
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

HER2 Expression in Gastric Adenocarcinoma: A Study in a Tertiary Care Centre in Bahrain

Maryam Hammad* and Aalaa Sayed Shubar
Department of Pathology, Salmaniya Medical Complex, Manama, Bahrain
*Corresponding Author: Maryam Hammad, Department of Pathology, Salmaniya Medical Complex, Manama, Bahrain, Email: [email protected]

Received Date: Apr 23, 2021 / Accepted Date: May 07, 2021 / Published Date: May 14, 2021

Citation: Hammad M, Shubar AS (2021) HER2 Expression in Gastric Adenocarcinoma: A Study in a Tertiary Care Centre in Bahrain. J Cancer Diagn 5:128.

Copyright: © 2021 Hammad M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

To read the full article Peer-reviewed Article PDF image


Aim: Stomach cancer is the fourth most common cancer worldwide. It is a significant cause for morbidity and mortality globally.HER2(Human Epidermal Growth Factor 2) status in gastric carcinoma has been studied worldwide, however there is sparse published data from Bahrain. Hence, this study was taken up to evaluate HER2 overexpression in gastric adenocarcinoma patients and to assess the relationship between its expression and clinicopathological tumor parameters.

Study design and settings: Retrospective study was conducted in Salmaniya Medical Complex-The main tertiary care center in Bahrain, over a 5 years period.

Study material: All the partial and complete gastric resection specimens and biopsies received in that period. HER-2 Immunohistochemistry (IHC) was done on most of the cases and the reports were reviewed for its expression in formalin-fixed paraffin-embedded tissue samples. Fluorescence In Situ Hybridization (FISH) was done for equivocal cases on IHC.

Data analysis: The data was analyzed using Microsoft Excel 2013.

Results: HER2 overexpression was confirmed in 4 (7.4%) cases of which 3 (75%) cases were of intestinal type whereas only 1 (25%) case of diffuse type adenocarcinoma.

Conclusion: HER2 positivity was more common in the intestinal type of gastric cancer compared to the diffuse type. Positivity of HER2 was found more in small biopsies as compared to the resection specimens in this study. HER2 overexpression was more in females, age more than 55 years old and in moderately and poorly differentiated adenocarcinoma. HER2 overexpression was not analyzed with the cancer stage because of data limitations.